Ackrell Capital Cannabis Investment Report predicts federal legalization timeline

Ackrell Capital Cannabis Investment Report predicts federal legalization timeline The passage offers generic predictions about FDA and DEA policy changes regarding cannabis without naming specific officials, transactions, or concrete evidence. It lacks actionable leads, novel revelations, or direct links to powerful actors, making it low-value for investigative follow‑up. Key insights: Mentions FDA acceptance of GW Pharmaceuticals' Epidiolex NDA in Oct 2017.; Notes DEA’s expanded registration policy and FDA botanical guidance updates.; Predicts six possible steps toward federal cannabis legalization.